이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Genfit 관리

관리 기준 확인 2/4

Genfit's CEO는 M. Prigent, Sep2019 에 임명되었습니다 의 임기는 4.75 년입니다. 총 연간 보상은 € 664.22K, 59.3% 로 구성됩니다. 59.3% 급여 및 40.7% 보너스(회사 주식 및 옵션 포함). 는 € 115.62K 가치에 해당하는 회사 주식의 0.062% 직접 소유합니다. 115.62K. 경영진과 이사회의 평균 재임 기간은 각각 2.4 년과 7 년입니다.

주요 정보

M. Prigent

최고 경영자

€664.2k

총 보상

CEO 급여 비율	59.3%
CEO 임기	4.8yrs
CEO 소유권	0.06%
경영진 평균 재임 기간	2.5yrs
이사회 평균 재임 기간	7.1yrs

최근 관리 업데이트

Recent updates

Genfit S.A.'s (EPA:GNFT) Price Is Right But Growth Is Lacking After Shares Rocket 28%

May 23

New Forecasts: Here's What Analysts Think The Future Holds For Genfit S.A. (EPA:GNFT)

Sep 30

Downgrade: Here's How Analysts See Genfit S.A. (EPA:GNFT) Performing In The Near Term

Jun 29

Genfit's(EPA:GNFT) Share Price Is Down 85% Over The Past Five Years.

Mar 14

Is Genfit (EPA:GNFT) A Risky Investment?

Nov 28

CEO 보상 분석

M. Prigent 의 보수는 Genfit 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Dec 31 2023	€664k	€394k	-€29m
Sep 30 2023	n/a	n/a	-€32m
Jun 30 2023	n/a	n/a	-€34m
Mar 31 2023	n/a	n/a	-€29m
Dec 31 2022	€632k	€375k	-€24m
Sep 30 2022	n/a	n/a	€12m
Jun 30 2022	n/a	n/a	€48m
Mar 31 2022	n/a	n/a	€58m
Dec 31 2021	€562k	€325k	€67m
Sep 30 2021	n/a	n/a	€14m
Jun 30 2021	n/a	n/a	-€39m
Mar 31 2021	n/a	n/a	-€70m
Dec 31 2020	€455k	€325k	-€101m
Sep 30 2020	n/a	n/a	-€84m
Jun 30 2020	n/a	n/a	-€67m
Mar 31 2020	n/a	n/a	-€66m
Dec 31 2019	€325k	€95k	-€65m

보상 대 시장: M. 의 총 보상 ($USD 713.76K )은 French 시장( $USD 534.67K ).

보상과 수익: 회사가 수익성이 없는 동안 M. 의 보상이 증가했습니다.

CEO

M. Prigent (55 yo)

4.8yrs

테뉴어

€664,224

보상

Mr. M. Pascal Prigent has been Chief Executive Officer of Genfit SA since September 16, 2019. He served as Executive Vice President of Marketing & Commercial Development at Genfit SA since May 31, 2018 unt...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jean-Francois Mouney	Co-Founder & Chairman of the Board	7.1yrs	€359.01k	0.094% € 178.9k
M. Prigent	Chief Executive Officer	4.8yrs	€664.22k	0.062% € 117.9k
Bart Staels	Co-Founder & Chairman of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Thomas Baetz	Chief Financial Officer	3.3yrs	데이터 없음	데이터 없음
Pascal Caisey	Chief Operating Officer	2.3yrs	데이터 없음	0.0095% € 18.1k
Meriam Kabbaj	Chief Technology Officer	1.6yrs	데이터 없음	데이터 없음
Dean Hum	Chief Scientific Officer	2.5yrs	€795.03k	0.021% € 39.5k
Jean-Christophe Marcoux	Chief Corporate Affairs Officer	1.3yrs	데이터 없음	0.0094% € 17.9k
Laurent Lannoo	Corporate Secretary & Director of Legal Affairs	16.5yrs	데이터 없음	0.023% € 43.1k
Stefanie Magner	Chief Compliance Officer & Executive VP of International Legal Affairs	3.3yrs	데이터 없음	0.0056% € 10.6k
Emilie Desodt	Executive Vice President of Human Resources	2.3yrs	데이터 없음	0.0035% € 6.7k
Sakina Sayah-Jeanne	Executive VP of Research & Translational Science	1.3yrs	데이터 없음	데이터 없음

2.5yrs

평균 재임 기간

52.5yo

평균 연령

경험이 풍부한 관리: GNFT 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jean-Francois Mouney	Co-Founder & Chairman of the Board	7.1yrs	€359.01k	0.094% € 178.9k
Bart Staels	Co-Founder & Chairman of the Scientific Advisory Board	no data	데이터 없음	데이터 없음
Philippe Moons	Board Observer	3.4yrs	€7.63k	0.0021% € 4.0k
Florence Séjourné	Director	7.1yrs	데이터 없음	데이터 없음
Scott L. Friedman	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Arun Sanyal	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Michael Trauner	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Catherine Larue	Independent Director	7.1yrs	€43.60k	데이터 없음
Vlad Raziu	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Anne-Helene Monsellato	Independent Director	7.1yrs	€39.24k	데이터 없음
Katherine Kalin	Independent Director	4yrs	€39.24k	0.010% € 19.2k
Eric Baclet	Independent Vice-Chairman of the Board	4yrs	€47.96k	0.0024% € 4.6k

7.1yrs

평균 재임 기간

62.5yo

평균 연령

경험이 풍부한 이사회: GNFT 의 이사회는 경험(평균 재직 기간 7 년)으로 간주됩니다.

Genfit 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Insufficient new directors

Genfit S.A., Annual General Meeting, May 22, 2024

GENFIT Announces Board Changes

Genfit SA, Annual General Meeting, May 28, 2021

Pascal Caisey and Philippe Motté Join the Executive Committee of GENFIT

Recent updates

Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis

New minor risk - Share price stability

Genfit S.A.'s (EPA:GNFT) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

New minor risk - Share price stability

Genfit S.A., Annual General Meeting, May 22, 2024

Genfit S.A.'s (EPA:GNFT) 26% Price Boost Is Out Of Tune With Revenues

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

Consensus EPS estimates fall by 15%

Consensus revenue estimates increase by 38%, EPS downgraded

GENFIT Announces Publication in Nature Medicine Confirming the Performance of Its Nash Diagnostic Technology

First half 2023 earnings released: €0.42 loss per share (vs €0.21 loss in 1H 2022)

Health Check: How Prudently Does Genfit (EPA:GNFT) Use Debt?

New minor risk - Profitability

Consensus EPS estimates increase by 291%

Genfit S.A. Announces the Publication of New Data on the Clinical Performance of NIS2+(TM) in Older Patients in Hepatology Communications

New minor risk - Profitability

Price target increased by 9.4% to €9.72

Revenue Downgrade: Here's What Analysts Forecast For Genfit S.A. (EPA:GNFT)

Consensus revenue estimates decrease by 21%

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

Price target increased by 9.4% to €9.70

New minor risk - Share price stability

Genfit S.A. (EPA:GNFT) Investors Are Less Pessimistic Than Expected

Price target decreased by 11% to €8.84

GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week as part of its ACLF Program

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.1% to €9.20

Genfit S.A. to Report First Half, 2023 Results on Sep 20, 2023

We Think Genfit (EPA:GNFT) Can Manage Its Debt With Ease

Consensus forecasts updated

New Forecasts: Here's What Analysts Think The Future Holds For Genfit S.A. (EPA:GNFT)

Genfit S.A. (ENXTPA:GNFT) acquired Versantis AG for approximately CHF 110 million.

First half 2022 earnings released: €0.21 loss per share (vs €0.21 profit in 1H 2021)

Genfit S.A. (ENXTPA:GNFT) agreed to acquire Versantis AG for approximately CHF 110 million.

Genfit S.A. (ENXTPA:GNFT) agreed to acquire Versantis AG from a group of investors for approximately CHF 110 million.

Consensus forecasts updated

Investor sentiment improved over the past week

Downgrade: Here's How Analysts See Genfit S.A. (EPA:GNFT) Performing In The Near Term

Consensus revenue estimates fall by 49%

Price target increased to €10.48

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 1,016%

Forecast to breakeven in 2022

Consensus forecasts updated

First half 2021 earnings released: EPS €0.21 (vs €1.36 loss in 1H 2020)

GENFIT Presents New NIS4® Data in NASH at the International Liver Congress™ and the 81St Scientific Sessions of the American Diabetes Association

GENFIT Announces the Launch of NASHnext®, a Novel, Noninvasive Diagnostic Test for Nonalcoholic Steatohepatitis

Full year 2020 earnings released: €2.61 loss per share (vs €1.76 loss in FY 2019)

Price target increased to €8.30

Full year 2020 earnings released

Genfit's(EPA:GNFT) Share Price Is Down 85% Over The Past Five Years.

GENFIT Announces Board Changes

Genfit SA to Report Fiscal Year 2020 Results on Apr 01, 2021

Price target raised to €8.20

Genfit SA, Annual General Meeting, May 28, 2021

New 90-day high: €5.20

GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of Hepatology

Pascal Caisey and Philippe Motté Join the Executive Committee of GENFIT

New 90-day high: €4.76

Robbins LLP Announces That Purchaser of Genfit SA American Depository Shares Filed Class Action Complaint Against the Company and Its Officers and Directors for Alleged Violations of the Securities Act of 1933

Is Genfit (EPA:GNFT) A Risky Investment?

Genfit Presents New Data at AASLD The Liver Meeting Digital Experience™

Analysts update estimates

Genfit and Labcorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic Test for Liver Disease

First half earnings released

GENFIT Announces First Patient First Visit for ELATIVE Phase 3 Study Evaluating Elafibranor in PBC

Genfit SA to Report First Half, 2020 Results on Sep 30, 2020